Tags

Type your tag names separated by a space and hit enter

Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Aliment Pharmacol Ther. 2009 May 01; 29(9):959-66.AP

Abstract

BACKGROUND

The ability to predict symptom response to reflux oesophagitis-healing therapy may optimize treatment decisions.

AIM

To identify factors associated with heartburn resolution in patients receiving acid-suppressive therapy for reflux oesophagitis.

METHODS

In this multicentre, randomized, double-blind trial (EXPO; AstraZeneca study code: SH-NEG-0008), patients with endoscopically confirmed reflux oesophagitis and reflux symptoms received once-daily proton pump inhibitor therapy [esomeprazole 40 mg (n = 1562) or pantoprazole 40 mg (n = 1589)] for >or=4 weeks. Factors associated with heartburn resolution after 4 weeks were identified by multiple logistic regression analysis.

RESULTS

Esomeprazole therapy, positive Helicobacter pylori status and greater age were associated with an increased likelihood of heartburn resolution [odds ratio (95% confidence interval): 1.31 (1.12, 1.54), 1.44 (1.19, 1.74) and 1.013 (1.007, 1.019) per year, respectively; all P < 0.001]. Men and patients with no acid regurgitation or epigastric pain pre-treatment were also more likely to achieve heartburn resolution (all P < 0.05).

CONCLUSIONS

The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy. Other factors, including H. pylori status, age, gender and symptom profile may be helpful in determining the likelihood of heartburn resolution in such patients.

Authors+Show Affiliations

Medical Department, Ev. Jung-Stilling Hospital, Siegen, Germany. J.Labenz@t-online.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19222417

Citation

Labenz, J, et al. "Clinical Trial: Factors Associated With Resolution of Heartburn in Patients With Reflux Oesophagitis--results From the EXPO Study." Alimentary Pharmacology & Therapeutics, vol. 29, no. 9, 2009, pp. 959-66.
Labenz J, Armstrong D, Zetterstrand S, et al. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther. 2009;29(9):959-66.
Labenz, J., Armstrong, D., Zetterstrand, S., Eklund, S., & Leodolter, A. (2009). Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Alimentary Pharmacology & Therapeutics, 29(9), 959-66. https://doi.org/10.1111/j.1365-2036.2009.03962.x
Labenz J, et al. Clinical Trial: Factors Associated With Resolution of Heartburn in Patients With Reflux Oesophagitis--results From the EXPO Study. Aliment Pharmacol Ther. 2009 May 1;29(9):959-66. PubMed PMID: 19222417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. AU - Labenz,J, AU - Armstrong,D, AU - Zetterstrand,S, AU - Eklund,S, AU - Leodolter,A, PY - 2009/2/19/entrez PY - 2009/2/19/pubmed PY - 2009/10/10/medline SP - 959 EP - 66 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 29 IS - 9 N2 - BACKGROUND: The ability to predict symptom response to reflux oesophagitis-healing therapy may optimize treatment decisions. AIM: To identify factors associated with heartburn resolution in patients receiving acid-suppressive therapy for reflux oesophagitis. METHODS: In this multicentre, randomized, double-blind trial (EXPO; AstraZeneca study code: SH-NEG-0008), patients with endoscopically confirmed reflux oesophagitis and reflux symptoms received once-daily proton pump inhibitor therapy [esomeprazole 40 mg (n = 1562) or pantoprazole 40 mg (n = 1589)] for >or=4 weeks. Factors associated with heartburn resolution after 4 weeks were identified by multiple logistic regression analysis. RESULTS: Esomeprazole therapy, positive Helicobacter pylori status and greater age were associated with an increased likelihood of heartburn resolution [odds ratio (95% confidence interval): 1.31 (1.12, 1.54), 1.44 (1.19, 1.74) and 1.013 (1.007, 1.019) per year, respectively; all P < 0.001]. Men and patients with no acid regurgitation or epigastric pain pre-treatment were also more likely to achieve heartburn resolution (all P < 0.05). CONCLUSIONS: The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy. Other factors, including H. pylori status, age, gender and symptom profile may be helpful in determining the likelihood of heartburn resolution in such patients. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/19222417/Clinical_trial:_factors_associated_with_resolution_of_heartburn_in_patients_with_reflux_oesophagitis__results_from_the_EXPO_study_ L2 - https://doi.org/10.1111/j.1365-2036.2009.03962.x DB - PRIME DP - Unbound Medicine ER -